{"transactions":[{"id":727405,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-24T21:20:17.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":5696,"price":8.159,"value":46473.664,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024, pursuant to a durable sale instruction. The sale does not represent a discretionary trade."}],"balance_after":187432,"source":{"system":"sec-edgar","filing":"0001628280-26-045286","document":"wk-form4_1782336014.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000162828026045286/wk-form4_1782336014.xml","form_type":"4"}},{"id":739302,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-12T20:15:16.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":77000,"derivative":{"exercise_price":1.22,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001616284-26-000002","document":"form4-06122026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000161628426000002/form4-06122026_040612.xml","form_type":"4"}},{"id":780412,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-13T20:18:24.000Z","date":"2026-05-11","kind":"sale","planned":false,"acquired":false,"shares":11139,"price":9.9374,"value":110692.6986,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade."}],"balance_after":193128,"source":{"system":"sec-edgar","filing":"0001628280-26-034615","document":"wk-form4_1778703501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000162828026034615/wk-form4_1778703501.xml","form_type":"4"}},{"id":873509,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-03T01:58:56.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February  26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the  Issuer on each vesting date."}],"balance_after":67000,"derivative":{"exercise_price":13.38,"expiration_date":"2036-02-25","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001628280-26-013531","document":"wk-form4_1772503133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000162828026013531/wk-form4_1772503133.xml","form_type":"4"}},{"id":873508,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-03T01:58:56.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the \"Plan\"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":204267,"source":{"system":"sec-edgar","filing":"0001628280-26-013531","document":"wk-form4_1772503133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000162828026013531/wk-form4_1772503133.xml","form_type":"4"}},{"id":895793,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-18T23:14:48.000Z","date":"2026-02-13","kind":"sale","planned":false,"acquired":false,"shares":5134,"price":11.89,"value":61043.26,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade."}],"balance_after":159267,"source":{"system":"sec-edgar","filing":"0001628280-26-009306","document":"wk-form4_1771456485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000162828026009306/wk-form4_1771456485.xml","form_type":"4"}},{"id":1102356,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-24T20:08:31.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":5700,"price":7.61,"value":43377.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on June 24, 2024."}],"balance_after":164401,"source":{"system":"sec-edgar","filing":"0001655759-25-000109","document":"wk-form4_1750795707.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575925000109/wk-form4_1750795707.xml","form_type":"4"}},{"id":1112967,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:19:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.75,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-25-016933","document":"form4-06122025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588925016933/form4-06122025_040612.xml","form_type":"4"}},{"id":1150391,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-05-13T21:17:50.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":91000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted by the Issuer on May 9, 2025, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":91000,"derivative":{"exercise_price":6.61,"expiration_date":"2035-05-08","underlying":"Common Stock","underlying_shares":91000},"source":{"system":"sec-edgar","filing":"0001655759-25-000091","document":"wk-form4_1747171064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575925000091/wk-form4_1747171064.xml","form_type":"4"}},{"id":1150390,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-13T21:17:50.000Z","date":"2025-05-09","kind":"grant","planned":false,"acquired":true,"shares":59600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the issuer on May 9, 2025, pursuant to its 2018 Stock Incentive Plan (the \"Plan\") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":170101,"source":{"system":"sec-edgar","filing":"0001655759-25-000091","document":"wk-form4_1747171064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575925000091/wk-form4_1747171064.xml","form_type":"4"}},{"id":1263269,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-02-19T00:59:46.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":74960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February  13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the  Issuer on each vesting date."}],"balance_after":74960,"derivative":{"exercise_price":17.67,"expiration_date":"2035-02-12","underlying":"Common Stock","underlying_shares":74960},"source":{"system":"sec-edgar","filing":"0001655759-25-000027","document":"wk-form4_1739926780.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575925000027/wk-form4_1739926780.xml","form_type":"4"}},{"id":1263268,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-19T00:59:46.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":49092,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the \"Plan\") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the  Issuer on each vesting date."}],"balance_after":110501,"source":{"system":"sec-edgar","filing":"0001655759-25-000027","document":"wk-form4_1739926780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575925000027/wk-form4_1739926780.xml","form_type":"4"}},{"id":1419774,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-08-29T20:15:16.000Z","date":"2024-08-28","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.45,"expiration_date":"2034-08-28","underlying":"Common Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-022537","document":"form4-08292024_040813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588924022537/form4-08292024_040813.xml","form_type":"4"}},{"id":1452355,"issuer":{"id":6561,"kind":"organization","name":"Milestone Pharmaceuticals Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-07-17T20:17:53.000Z","date":"2024-07-15","kind":"grant","planned":false,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest in equal monthly installments, beginning on August 15, 2024, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date."}],"balance_after":80000,"derivative":{"exercise_price":1.585,"expiration_date":"2034-07-15","underlying":"Common Shares","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001415889-24-019668","document":"form4-07172024_080740.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1408443/000141588924019668/form4-07172024_080740.xml","form_type":"4"}},{"id":1468592,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-26T20:20:59.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":94418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted by the Issuer on June 24, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4) and not pursuant the Plan. The shares underlying the option will vest over four years: 1/4 of the shares underlying the award shall vest on June 24, 2025, with the remainder of the shares vesting in equal monthly installments following June 24, 2025 through June 24, 2028."}],"balance_after":94418,"derivative":{"exercise_price":24.97,"expiration_date":"2034-06-23","underlying":"Common Stock","underlying_shares":94418},"source":{"system":"sec-edgar","filing":"0001655759-24-000105","document":"wk-form4_1719433252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575924000105/wk-form4_1719433252.xml","form_type":"4"}},{"id":1468591,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-26T20:20:59.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":61409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (each, an \"RSU\") were granted by the Issuer on June 24, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), and not pursuant to its 2018 Stock Incentive Plan (the \"Plan\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of June 24, 2025,  June 24, 2026, June 24, 2027 and  June 24, 2028, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":61409,"source":{"system":"sec-edgar","filing":"0001655759-24-000105","document":"wk-form4_1719433252.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616284/000165575924000105/wk-form4_1719433252.xml","form_type":"4"}},{"id":1743560,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:15.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72540,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":20.84,"underlying":"Common Stock","underlying_shares":72540},"source":{"system":"sec-edgar","filing":"0001104659-23-117093","document":"tm2330435-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117093/tm2330435-1_4seq1.xml","form_type":"4"}},{"id":1743559,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:15.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":18.4,"underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-23-117093","document":"tm2330435-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117093/tm2330435-1_4seq1.xml","form_type":"4"}},{"id":1743558,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-11-13T14:40:15.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":14.44,"underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001104659-23-117093","document":"tm2330435-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117093/tm2330435-1_4seq1.xml","form_type":"4"}},{"id":1743557,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-13T14:40:15.000Z","date":"2023-11-08","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45244,"price":19,"value":859636.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117093","document":"tm2330435-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117093/tm2330435-1_4seq1.xml","form_type":"4"}},{"id":1743556,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-13T14:40:15.000Z","date":"2023-11-08","kind":"other","planned":false,"acquired":false,"shares":23021,"price":19,"value":437399.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. (\"Alfasigma\"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma (\"Purchaser\"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer (\"Company Common Stock\") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the \"Effective Time\"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-23-117093","document":"tm2330435-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923117093/tm2330435-1_4seq1.xml","form_type":"4"}},{"id":1773883,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-09-25T16:01:09.000Z","date":"2023-09-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":908,"price":10.8,"value":9806.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":68265,"source":{"system":"sec-edgar","filing":"0001104659-23-103508","document":"tm2326871-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923103508/tm2326871-1_4seq1.xml","form_type":"4"}},{"id":1845049,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-06-23T16:04:29.000Z","date":"2023-06-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":908,"price":11.74,"value":10659.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":69173,"source":{"system":"sec-edgar","filing":"0001104659-23-074233","document":"tm2319483-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923074233/tm2319483-1_4seq1.xml","form_type":"4"}},{"id":1940051,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-23T16:01:09.000Z","date":"2023-03-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":909,"price":14.19,"value":12898.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":70081,"source":{"system":"sec-edgar","filing":"0001104659-23-036043","document":"tm2310362-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923036043/tm2310362-1_4seq1.xml","form_type":"4"}},{"id":2040124,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2023-01-31T16:05:30.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2023."}],"balance_after":24000,"derivative":{"exercise_price":18.4,"expiration_date":"2033-01-27","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001104659-23-008588","document":"tm234878-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923008588/tm234878-6_4seq1.xml","form_type":"4"}},{"id":2040123,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-31T16:05:30.000Z","date":"2023-01-27","kind":"grant","acquired":true,"shares":14700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2023."}],"balance_after":70990,"source":{"system":"sec-edgar","filing":"0001104659-23-008588","document":"tm234878-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923008588/tm234878-6_4seq1.xml","form_type":"4"}},{"id":2072350,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-03T16:04:22.000Z","date":"2022-12-31","kind":"tax_withholding","acquired":false,"shares":718,"price":12.37,"value":8881.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of restricted stock unit awards previously granted to the reporting person."}],"balance_after":56290,"source":{"system":"sec-edgar","filing":"0001104659-23-000337","document":"tm231319-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465923000337/tm231319-6_4seq1.xml","form_type":"4"}},{"id":2076674,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-23T16:03:45.000Z","date":"2022-12-21","kind":"tax_withholding","acquired":false,"shares":908,"price":13.43,"value":12194.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":57008,"source":{"system":"sec-edgar","filing":"0001104659-22-129883","document":"tm2233418-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922129883/tm2233418-1_4seq1.xml","form_type":"4"}},{"id":2151912,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-09-23T16:02:04.000Z","date":"2022-09-21","kind":"tax_withholding","acquired":false,"shares":908,"price":14.85,"value":13483.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":57916,"source":{"system":"sec-edgar","filing":"0001104659-22-102662","document":"tm2226480-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922102662/tm2226480-1_4seq1.xml","form_type":"4"}},{"id":2222922,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-06-23T16:01:47.000Z","date":"2022-06-21","kind":"tax_withholding","acquired":false,"shares":3632,"price":12.48,"value":45327.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock unit award previously granted to the reporting person."}],"balance_after":58824,"source":{"system":"sec-edgar","filing":"0001104659-22-073886","document":"tm2219176-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922073886/tm2219176-1_4seq1.xml","form_type":"4"}},{"id":2421001,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2022-01-31T16:16:00.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":17600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2022."}],"balance_after":17600,"derivative":{"exercise_price":14.44,"expiration_date":"2032-01-27","underlying":"Common Stock","underlying_shares":17600},"source":{"system":"sec-edgar","filing":"0001104659-22-009563","document":"tm224882-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922009563/tm224882-8_4seq1.xml","form_type":"4"}},{"id":2421000,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-31T16:16:00.000Z","date":"2022-01-27","kind":"grant","acquired":true,"shares":10300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2022."}],"balance_after":62456,"source":{"system":"sec-edgar","filing":"0001104659-22-009563","document":"tm224882-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465922009563/tm224882-8_4seq1.xml","form_type":"4"}},{"id":2658624,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-06-22T19:01:42.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":72540,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the options subject to the award will vest and become exercisable on the first anniversary of the Vesting Commencement Date, and the remaining options will vest and become exercisable in equal monthly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 21, 2021."}],"balance_after":72540,"derivative":{"exercise_price":20.84,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":72540},"source":{"system":"sec-edgar","filing":"0001104659-21-084279","document":"tm2120362-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921084279/tm2120362-2_4seq1.xml","form_type":"4"}},{"id":2658623,"issuer":{"id":108343,"kind":"organization","name":"INTERCEPT PHARMACEUTICALS, INC.","symbol":"ICPT"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-22T19:01:42.000Z","date":"2021-06-21","kind":"grant","acquired":true,"shares":52156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the shares subject to the award will vest on the first anniversary of the Vesting Commencement Date, and the remaining shares will vest in equal quarterly installments in arrears over the three-year period commencing on the first anniversary of the Vesting Commencement Date and ending on the fourth anniversary of the Vesting Commencement Date. The Vesting Commencement Date is June 21, 2021."}],"balance_after":52156,"source":{"system":"sec-edgar","filing":"0001104659-21-084279","document":"tm2120362-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1270073/000110465921084279/tm2120362-2_4seq1.xml","form_type":"4"}},{"id":2685848,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-02T20:31:40.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":3017,"price":3.3575,"value":10129.5775,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were acquired under the Issuer's Employee Share Purchase Plan (\"ESPP\") for the ESPP purchase period beginning on December 1, 2020 and ending on May 31, 2021 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's ordinary shares on May 28, 2021 (the last trading day of the offering period)."}],"balance_after":116468,"source":{"system":"sec-edgar","filing":"0001209191-21-037193","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121037193/doc4.xml","form_type":"4"}},{"id":2760438,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T16:14:32.000Z","date":"2021-03-31","kind":"tax_withholding","acquired":false,"shares":762,"price":6.84,"value":5212.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units."}],"balance_after":113451,"source":{"system":"sec-edgar","filing":"0001209191-21-024410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121024410/doc4.xml","form_type":"4"}},{"id":2835138,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2021-02-24T21:39:07.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":68162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":68162,"derivative":{"exercise_price":8.33,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":68162},"source":{"system":"sec-edgar","filing":"0001209191-21-013814","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013814/doc4.xml","form_type":"4"}},{"id":2835137,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-24T21:39:07.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":29213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on March 31, 2022 and 6.25% every three months thereafter, ending on March 31, 2025."}],"balance_after":114213,"source":{"system":"sec-edgar","filing":"0001209191-21-013814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919121013814/doc4.xml","form_type":"4"}},{"id":3036280,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-09-09T00:01:09.000Z","date":"2020-09-08","kind":"purchase","acquired":true,"shares":40000,"price":1.462,"value":58480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were purchased in multiple transactions at prices ranging from $1.4499 to $1.4767 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":340000,"source":{"system":"sec-edgar","filing":"0001209191-20-049796","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120049796/doc4.xml","form_type":"4"}},{"id":3155997,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2020-05-08T21:54:04.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":250000,"derivative":{"exercise_price":1.95,"expiration_date":"2030-05-06","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-20-028037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028037/doc4.xml","form_type":"4"}},{"id":3155996,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-05-08T21:54:04.000Z","date":"2020-05-06","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo Therapeutics Inc."},{"field":"shares","element":"transactionShares","label":"F2","text":"The awards vest over four years, 25% on June 30, 2021 and 6.25% every three months thereafter, ending on June 30, 2024."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001209191-20-028037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120028037/doc4.xml","form_type":"4"}},{"id":3196012,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options","published_at":"2020-03-24T20:31:17.000Z","date":"2020-03-23","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest and become exercisable over a period of four years (25% on March 31, 2021 and 6.25% every three months thereafter), ending March 31, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":100000,"derivative":{"exercise_price":3.13,"expiration_date":"2030-03-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-020935","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120020935/doc4.xml","form_type":"4"}},{"id":3196011,"issuer":{"id":6871,"kind":"organization","name":"Yarrow Bioscience, Inc."},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-03-24T20:31:17.000Z","date":"2020-03-23","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects restricted stock units, each of which represents a contingent right to receive one share of Issuer common stock, subject to continued service to the Issuer."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-20-020935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1566044/000120919120020935/doc4.xml","form_type":"4"}},{"id":3263130,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-02-19T21:30:27.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":38400,"price":1.3,"value":49920.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on February 14, 2020."}],"balance_after":42549,"source":{"system":"sec-edgar","filing":"0001140361-20-003645","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000114036120003645/form4.xml","form_type":"4"}},{"id":3497132,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"director":true,"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right To Purchase)","published_at":"2019-06-07T21:41:30.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":62715,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, representing a right to purchase a total of 62,715 shares of Common Stock, will become exercisable on June 6, 2020, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date."}],"balance_after":62715,"derivative":{"exercise_price":6.39,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":62715},"source":{"system":"sec-edgar","filing":"0001127602-19-021141","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219021141/form4.xml","form_type":"4"}},{"id":3590497,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2019-03-18T21:55:26.000Z","date":"2019-03-15","kind":"exercise","acquired":false,"shares":82999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of RSUs granted to the Reporting Person on August 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":82999},"source":{"system":"sec-edgar","filing":"0001127602-19-011939","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219011939/form4.xml","form_type":"4"}},{"id":3590496,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-03-18T21:55:26.000Z","date":"2019-03-15","kind":"exercise","acquired":true,"shares":82999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of RSUs granted to the Reporting Person on August 14, 2018."}],"balance_after":82999,"source":{"system":"sec-edgar","filing":"0001127602-19-011939","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219011939/form4.xml","form_type":"4"}},{"id":3843286,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2018-08-15T11:57:11.000Z","date":"2018-08-14","kind":"grant","acquired":true,"shares":82999,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest."}],"balance_after":82999,"derivative":{"underlying":"Common Stock","underlying_shares":82999},"source":{"system":"sec-edgar","filing":"0001127602-18-025368","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760218025368/form4.xml","form_type":"4"}},{"id":3887134,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right To Purchase)","published_at":"2018-06-20T20:19:49.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":166001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These options expire on the third anniversary of the vesting date."}],"balance_after":166001,"derivative":{"exercise_price":1.1,"underlying":"Common Stock","underlying_shares":166001},"source":{"system":"sec-edgar","filing":"0001127602-18-021571","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760218021571/form4.xml","form_type":"4"}},{"id":4014995,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right To Purchase)","published_at":"2018-03-05T13:27:18.000Z","date":"2018-03-01","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, representing a right to purchase a total of 50,000 shares of Common Stock, will become exercisable on March 1, 2019, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":14.98,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001127602-18-009814","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760218009814/form4.xml","form_type":"4"}},{"id":4172711,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35598,"kind":"person","name":"Saik Andrew","position":1,"cik":"0001616284","reported_name":"Saik Andrew","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right To Purchase)","published_at":"2017-11-03T22:03:27.000Z","date":"2017-11-01","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option, representing a right to purchase a total of 200,000 shares of Common Stock, will become exercisable on October 31, 2018, with 25% vesting on that date and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date."}],"balance_after":200000,"derivative":{"exercise_price":10.73,"expiration_date":"2027-11-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001127602-17-031259","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760217031259/form4.xml","form_type":"4"}}]}